Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- POCT Market to Expand from 2003
December 31, 2001
- Price Discrepancy Rates Vary 5.7% to 9.6% According to Therapeutic Category
December 31, 2001
- WORLD NEWA IN BRIEF
December 31, 2001
- Chuikyo Recommends Price Cut for Long-listed Products
December 31, 2001
- Original Drugs with Generics Only to Be Subject to Additional Price Cut
December 31, 2001
- REGULATORY NEWS IN BRIEF
December 31, 2001
- Kissei, Novartis Make Alliance for Agent for Glaucoma
December 31, 2001
- Sankyo to Copromote CS-866 with Forest Laboratories in US
December 31, 2001
- S-P to Increase Its MRs to 600 to Detail Ribavirin
December 31, 2001
- GSK's Flutide Diskus Included in NHI Price List
December 31, 2001
- The Year 2001 in Retrospect:
December 31, 2001
- BUSINESS NEWS IN BRIEF
December 31, 2001
- Innovation and Reward - Contributing to a Healthy and Growing Economy
December 31, 2001
- Takara Shuzo Develops New Gene Transfer Technology, rPIC Method
December 31, 2001
- Perspective for 2002
December 31, 2001
- J&J: New Breast Cancer Biopsy System
December 31, 2001
- FALCO Biosystems Certified by CAP
December 24, 2001
- GL on Stroke Treatment Under Preparation: Seminar
December 24, 2001
- Main Reason for Merger Is to Add Value: Mr Burns of Roche
December 24, 2001
- Steroid Nasal Drops Effective against Japanese Cedar Pollinosis: GSK Seminar
December 24, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…